Catalent (NYSE: CTLT) reported Q1 EPS of $0.21, $0.03 better than the analyst estimate of $0.18. Revenue for the quarter came in at $543.9 million versus the consensus estimate of $490.89 million.

Management is updating its guidance, which will now reflect the recently completed acquisition of Cook Pharmica, which closed on October 23, 2017. For fiscal year 2018, the company expects revenuein the range of $2.31 billion to $2.41 billion. Catalent expects Adjusted EBITDA in the range of $521 million to $547 million and Adjusted Net Income in the range of $198 million to $224 million. The Company expects self-funded capital expenditures in the range of $152 million to $165 million and fully diluted share count in the range of 133 million to 135 million shares on a weighted-average basis.

For earnings history and earnings-related data on Catalent (CTLT) click here.